Entrectinib has been granted a priority review designation by the FDA as a therapy for select adult and pediatric patients with NTRK fusion–positive locally advanced or metastatic solid tumors, as well as patients with metastatic ROS1-positive non–small cell lung cancer, according to Genentech, the developer of the multikinase inhibitor.